RICT 2015<br />Drug Discovery and Selection

The scientific programme of RICT 2015 is now available on the website!

Conferences > Archives > RICT 2015

Confirmed Speakers


Confirmed Speakers

Covalent Kinase Inhibitors: A Practical Guide to Molecular Trapping
Dr Tjeerd BARFDr Tjeerd BARF
(ACERTA PHARMA BV, Oss, The Netherlands)

Read more
Resistance Phenotypes and SAR in HCV Drug Development
Dr John BILELLODr John BILELLO
(MERCK, Whitehouse Station, United States)

Read more
Shedding Light on Protein Kinase Plasticity
Prof. Pascal BONNETProf. Pascal BONNET
(UNIVERSITY OF ORLÉANS, Orléans, France)

Read more
Chemical Probes for Epigenetic Proteins
Prof. Paul BRENNANProf. Paul BRENNAN
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

Read more
Two Steps Forward, One Step Back: Successes and Failures in Structure-based Discovery of GPCR Ligands
Prof. Jens CARLSSONProf. Jens CARLSSON
(STOCKHOLM UNIVERSITY, Stockholm, Sweden)

Read more
Discovery and Characterisation of Potent and Selective Inhibitors of ATR Kinase as Anti-cancer Agents
Mr Jean-Damien CHARRIERMr Jean-Damien CHARRIER
(VERTEX PHARMACEUTICALS, OXON, United Kingdom)

Read more
Fragment and Structure-Based Drug Discovery for a Family C GPCR: Discovery of the mGlu5 NAM Pre-clinical Candidate HTL14242
Dr John CHRISTOPHERDr John CHRISTOPHER
(HEPTARES, Hertfordshire, United Kingdom)

Read more
Antibiotic Resistance is an Emerging Disease
Dr Patrice COURVALINDr Patrice COURVALIN
(INSTITUT PASTEUR, Paris, France)

Read more
From in situ Click to in vivo: Effect of Inhibition of Insulin Degrading Enzyme
Prof. Rebecca DEPREZ-POULAINProf. Rebecca DEPREZ-POULAIN
(UNIVERSITY OF LILLE, Lille, France)

Read more
Cerdelga, an Oral Therapy for Gaucher’s Disease; from Discovery to Launch
Dr David J HARRISDr David J HARRIS
(SANOFI, Waltham, United States)

Read more
Retinoids/Steroids as Ligands for Pharmacological Chaperon and Protein Knockdown Approach
Prof. Yuichi HASHIMOTOProf. Yuichi HASHIMOTO
(THE UNIVERSITY OF TOKYO, Tokyo, Japan)

Read more
Lessons learned in TB Drug Discovery
Dr Jan JIRICEKDr Jan JIRICEK
(NOVARTIS INSTITUTE FOR TROPICAL DISEASES, Singapore, Singapore)

Read more
BAY 1067197 - Discovery of a Partial Adenosine A1 Agonist for the Treatment of Heart Failure
Dr Daniel MEIBOMDr Daniel MEIBOM
(BAYER PHARMA, Wuppertal, Germany)

Read more
Novel Triazolopyridine Compounds as Selective JAK1 Inhibitors: From Target Discovery to Filgotinib
Dr Christel MENETDr Christel MENET
(GALAPAGOS, Brussels, Belgium)

Read more
Paul Ehrlich Awardee - The Synthetic Peptide P140, a Skilled Strategist and Manipulator of the Immune System
Dr Sylviane MULLERDr Sylviane MULLER
(IBMC-CNRS, Strasbourg, France)

Read more
Revolutionary Idea Yielded SGLT2 Inhibitor Canagliflozin for Treatment of Type 2 Diabetes
Dr Sumihiro NOMURADr Sumihiro NOMURA
(MITSUBISHI TANABE PHARMA CORPORATION, Saitama, Japan)

Read more
Drugs, Targets, Diseases and the Druggable Proteome
Prof. Tudor I. OPREAProf. Tudor I. OPREA
(UNIVERSITY OF NEW MEXICO, Albuquerque, United States)

Read more
Phenotypic Screening for the Discovery of Novel Molecules for Therapeutic Cardiac Regeneration
Dr Alleyn T. PLOWRIGHTDr Alleyn T. PLOWRIGHT
(ASTRAZENECA, Cambridge, United Kingdom)

Read more
Pierre Fabre Awardee - Small Molecules, Big Players
Dr Raphaël RODRIGUEZDr Raphaël RODRIGUEZ
(INSTITUT CURIE, Paris, France)

Read more
Sofosbuvir: A Breakthrough Curative Therapy for HCV
Dr Michael SOFIADr Michael SOFIA
(TEKMIRA/ONCORE BIOPHARMA, Doylestown, PA, United States)

Read more
Synthetic Molecules for Cell Biology and Cell Therapy
Prof. Motonari UESUGIProf. Motonari UESUGI
(KYOTO UNIVERSITY, Kyoto, Japan)

Read more
Locking the Bioactive Conformation – Discovery of BAY 85-8501, a Potent Inhibitor of Human Neutrophil Elastase
Dr Franz VON NUSSBAUMDr Franz VON NUSSBAUM
(BAYER PHARMA, Berlin, Germany)
Discovery of HIV Integrase Inhibitors
Dr John WAIDr John WAI
(WUXI APPTEC, Shanghai, China)

Read more

Short Communications

How do a Proapoptotic and a Cell Penetration Peptide work Together to kill Cancer Cells?
Dr Isabel ALVESDr Isabel ALVES
(UNIVERSITY OF BORDEAUX, Pessac, France)

Read more
Development of Unnatural Basic Amino Acids Leading to Orally-Active NPFF Receptor Antagonists Preventing Opioid-Induced Hyperalgesia during the Treatment of Acute or Chronic Pains
Dr Frédéric BIHELDr Frédéric BIHEL
(CNRS / UNIVERSITY OF STRASBOURG, Illkirch, France)

Read more
Allosteric Inhibitors of p38 MAPK-MK2 Pathway for Selective Cancer Cell Killing
Dr Lenka MUNOZDr Lenka MUNOZ
(UNIVERSITY OF SYDNEY, Sydney, Australia)

Read more
Development of Novel Multi-Target Directed Ligands for Alzheimer's Disease: Identification of Donecopride
Prof. Christophe ROCHAISProf. Christophe ROCHAIS
(UNIVERSITY OF CAEN, Caen, France)

Read more

Organised by

With the support of

EFMC Sponsored Event

Major Sponsors

Sponsors

Media Partners

Copyright 2021 LD Organisation srl  |  rue Michel de Ghelderode 33/02 B-1348  Louvain-la-Neuve (Belgium)  Tel. +32 (0)10 45 47 77  |   |  VAT: BE 0464819842
Developed and powered by Antalys